Quality Medical Research | Nashville Office

Research site

About

Quality Medical Research is a clinical research center located in the Nashville metro area. We are dedicated to conducting innovative clinical studies addressing a wide spectrum of common diseases. Our primary mission is to provide access to healthcare by offering affordable medications and treatments that meet the needs of patients from diverse backgrounds. Whether you are a sponsor for clinical trials, a potential participant, or an industry expert, we encourage you to discover more about our organization.

Location

330 Wallace Rd Suite 103, Nashville, Tennessee, United States of America

Website

https://thegidocs.com/research/

Site insights

Top conditions

Top treatments

Selonsertib

Upadacitinib

Relamorelin

Firsocostat

Filgotinib

ABT-494

Cilofexor

LY3841136

Metoclopramide

Risankizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Christina Stanley

Verified by this site

Active trials

13 of 65 total trials

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess th...

Enrolling

Chronic Idiopathic Constipation (CIC)

Drug: Tenapanor 50 mg BID

Drug: Tenapanor 5 mg BID

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling

Overweight

Obesity

Drug: LY3549492

Drug: LY3305677

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in...

Active, not recruiting

Coeliac Disease

Celiac Disease

Dietary Supplement: SIGE

Drug: Placebo

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participant...

Enrolling

Eosinophilic Esophagitis

Drug: Placebo

Drug: Vonoprazan

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (AFFIRM)

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Active, not recruiting

Crohn's Disease

Drug: Placebo for risankizumab

Drug: Risankizumab SC

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP)

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling

Ulcerative Colitis

Drug: Risankizumab

Drug: Vedolizumab

Locations recently updated

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1)

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) co...

Active, not recruiting

Moderately to Severely Active Ulcerative Colitis

Drug: Afimkibart

Drug: Placebo

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance...

Enrolling

Moderately to Severely Active Crohns Disease

Drug: Placebo

Drug: Afimkibart

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study...

Active, not recruiting

Ulcerative Colitis

Drug: IV Placebo

Drug: SC Placebo

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling

Crohn's Disease

Other: SC Placebo

Drug: IV Tulisokibart

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: LY3549492

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: LY3841136

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis (SWIFT)

The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compar...

Active, not recruiting

Ulcerative Colitis

Drug: GS-1427

Drug: Placebo-to-match GS-1427